Eczema Drug Restores Nails in Boy With Rare 19-Nail Dystrophy, Case Report Shows

A seven-year-old boy in China whose fingernails and toenails had been slowly destroyed since he was three weeks old has regained nearly normal nails after treatment with dupilumab, a monoclonal antibody best known as the first biologic approved for moderate-to-severe atopic dermatitis. The case, published in Frontiers in Medicine by dermatologists at the First Hospital of Hebei Medical University, is striking not only because 19 of the child’s 20 nails were affected, but because he never developed the eczematous skin lesions that usually accompany atopic disease. The nail unit was the only visibly diseased tissue on his entire body, a presentation so unusual that published reports of comparable pediatric cases remain scarce.

Onychodystrophy, the descriptive term for abnormal nail structure or growth, is not a diagnosis in itself. It can arise from damage to any component of the nail unit, including the nail matrix where the plate is generated, the nail bed beneath it, the plate itself, or the surrounding nail folds. One characteristic pattern, trachyonychia, produces rough, dull, longitudinally ridged or fissured plates and reflects disrupted keratinization within the matrix. Pediatric nail disorders are relatively common, with prevalence estimates in earlier studies ranging from roughly 3 to 11 percent, and while most are benign and self-limited, some signal an underlying dermatologic, systemic, or genetic condition. The differential diagnosis in children includes atopic dermatitis, psoriasis, lichen planus, alopecia areata, vitiligo, and fungal onychomycosis, each with its own treatment implications.

The boy’s history made the diagnosis genuinely difficult. His guardians first noticed nail abnormalities at three weeks of age, and the changes gradually spread until, at presentation in October 2025, 19 nails showed marked thickening, irregular roughening, and yellow-brown opaque discoloration. Only the right fifth toenail was spared, and there was no periungual erythema or soft-tissue swelling. Dermoscopy revealed irregular whitish patches, nail fissuring, and fine longitudinal grooves. He had previously been treated with desonide cream and 0.03 percent tacrolimus ointment, each applied once daily, without satisfactory response, and his guardians declined oral corticosteroids over concerns about systemic side effects. He carried a diagnosis of allergic rhinitis, but there was no relevant family history of hereditary disease, hepatitis, or tuberculosis.

Laboratory workup pointed toward a type 2 inflammatory process. The boy’s eosinophil percentage was 9.7 percent against a reference range of 0 to 0.9 percent, his absolute eosinophil count was elevated at 0.8 times ten to the ninth per liter, and his serum immunoglobulin E was mildly raised at 172.1 IU/mL with a reference maximum of 60. Allergen testing showed sensitization to beef, mites, and mold. To rule out fungal infection, clinicians performed direct microscopy and fungal culture of nail clippings three times at one-month intervals, all consistently negative, although PAS staining and fungal PCR were unavailable. His parents refused a nail biopsy out of concern about causing permanent dystrophy. With infection excluded, biopsy unavailable, and an atopic history in hand, the team settled on atopic dermatitis-associated nail involvement as a possible diagnosis, a conclusion the authors emphasize was probabilistic rather than definitive.

Dupilumab works by binding the interleukin-4 receptor alpha subunit, blocking signaling from both interleukin-4 and interleukin-13, the two cytokines that drive type 2 inflammation, the immune pathway central to atopic dermatitis. By suppressing that pathway, the drug improves epidermal barrier dysfunction and reduces itch. After parental consent, the boy received a 400 mg loading dose followed by 200 mg every two weeks, combined with topical crisaborole ointment twice daily for two weeks. At 16 weeks, early signs of healthy nail regrowth appeared. By 32 weeks, the affected nails had nearly regained normal morphology, thickness, and coloration, and his quality-of-life and itch scores, measured on the Children’s Dermatology Life Quality Index and the Peak Pruritus Numerical Rating Scale, fell from 12 and 5 to 2 and 1. No adverse events were observed through eight months of follow-up.

The therapeutic response is scientifically meaningful because it supports, indirectly, the idea that subclinical type 2 inflammation within the nail unit drove the dystrophy. In atopic disease, Th2-derived cytokines such as IL-4, IL-13, and IL-31 sustain a chronic inflammatory microenvironment. Previous reports suggest that periungual eczema and pruritus can precede nail changes: inflamed skin around the nail folds impairs the local barrier, scratching mechanically injures the nail unit, and soaps and detergents compound the damage, together disturbing normal plate formation. What makes this case exceptional is that none of that periungual inflammation was clinically visible. The authors acknowledge that without histopathological or molecular evidence from the nail unit itself, the proposed mechanism remains speculative, but the failure of topical tacrolimus and corticosteroids followed by marked improvement on dupilumab strengthens the case for IL-4 and IL-13 as key mediators.

The report also reviews the growing, though still thin, literature on dupilumab-treated nail dystrophy. A narrative search identified six published reports covering ten patients, five single adult cases and one pediatric series of five children aged four to eight. Adult outcomes illustrate how slowly nails recover: a 55-year-old woman with median canaliform dystrophy of the thumbnail achieved complete remission by four months, a 57-year-old woman with five dystrophic fingernails and marked periungual inflammation required roughly a year to reach largely normal morphology, and a 40-year-old woman with twenty-nail dystrophy showed near-complete recovery at five months except for the thumbnails. In the pediatric series, all five children improved substantially, with several showing almost complete normalization by week 12 and durable control at week 24 to 30.

One instructive anomaly emerged from the literature review. In one adult patient, nail abnormalities actually worsened after dupilumab initiation before gradually improving with continued treatment, a course the original authors did not consider a true adverse drug reaction. Similar nail-related adverse events have not appeared in dupilumab clinical trials, so the case-report authors caution clinicians against interpreting early worsening alone as treatment failure or discontinuing the drug on that basis. Another practical point concerns timing: nail improvement typically lags behind skin and itch responses because recovery depends on the physical rate of nail growth, meaning follow-up should span at least one complete nail growth cycle before judging efficacy.

The case’s broader lesson is diagnostic humility. Extensive nail dystrophy in a child without eczema could equally suggest nail psoriasis, which affects an estimated 10 to 80 percent of psoriasis patients and presents with thimble-like pitting, splinter hemorrhages, and oil-drop discoloration, or nail lichen planus, which causes thinning, longitudinal ridging, dorsal pterygium, and distal splitting in about 10 percent of cutaneous lichen planus cases. Alopecia areata produces smaller, shallower, grid-like pitting often alongside hair loss, while onychomycosis demands mycological confirmation. The authors stress that diagnosis must integrate the nail phenotype with cutaneous findings, clinical history, and systematic exclusion of alternatives, since the severity of nail change does not necessarily track the severity of any associated skin disease.

The authors are careful about the limits of their evidence. A favorable response to dupilumab strengthens the possibility of an atopic contribution but does not establish the diagnosis, and conclusions from the wider literature remain constrained by small samples, heterogeneous follow-up, non-standardized outcome assessment, and scarce histopathological confirmation. Still, for a condition in which topical therapies failed and families often refuse invasive biopsy, the report suggests a practical pathway: when an atopic background is clinically suspected, targeted blockade of type 2 inflammation may restore nails that conventional treatment could not save. Larger prospective studies with defined outcome measures will be needed to determine which nail-dystrophy phenotypes truly benefit, but this single child’s recovery from near-total nail destruction adds a compelling data point to a rapidly evolving area of dermatology.

Subject of Research: Dupilumab treatment of extensive pediatric nail dystrophy in an atopic patient

Article Title: Nineteen nail dystrophy in an atopic background responsive to dupilumab: a case report

Article References: Zang, Y., Li, X., Li, H., Qi, J., Zhu, Q., & Zhang, G. (2026). Nineteen nail dystrophy in an atopic background responsive to dupilumab: a case report. Frontiers in Medicine, 13, Article 1938551. https://doi.org/10.3389/fmed.2026.1938551

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.1938551

Keywords: dupilumab, nail dystrophy, onychodystrophy, atopic dermatitis, pediatrics, dermatology, type 2 inflammation, interleukin-4, trachyonychia, case report, biologics, immune dysregulation